VALARTH See Divis Laboratories in the appOpen in app
DIVISLAB · NSE · Pharmaceuticals

Divis Laboratories Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Large Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
dear low confidence No valuation within 120 days; P/E 84.8 vs peers 31.2 (11th of 12); P/B 9.4 vs peers 3.7 (9th of 12).
Statements through FY2026Prices adjusted for 3 corporate actionsNot yet reviewed by the adversarial model

What is Divis Laboratories's share price today?

Divis Laboratories last traded at ₹9,426.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, up 0.9% on the day, up 42.5% over a year. Its 52-week range is ₹5,648 to ₹9,740. The live price is in the app.

₹9,426.00 +0.9% today
+42.5% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range92% of the way up
Low ₹5,648High ₹9,740

What is Divis Laboratories's market cap?

Divis Laboratories's market capitalisation is about ₹2.48 lakh crore: what it would cost to buy every share at today's price. That makes it the 35th largest large cap company we cover.

₹2.5 L Cr Large Cap35th largest large cap company
Large Cap means the 100 largest listed companies, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: DIVISLAB
ISIN
INE361B01024
Cap bucket
Large Cap, 35th largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
2003
Futures and options
Traded

Is Divis Laboratories overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 84.8 vs peers 31.2 (11th of 12); P/B 9.4 vs peers 3.7 (9th of 12).

Valuation

Latest price and trailing 12 months
P/E 84.75
vs peers 31.2 · 11th of 12
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 9.43
vs peers 3.7 · 9th of 12
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹2.48 lakh Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 0.5%
vs peers 0.6% · 6th of 10
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) 3.62
vs peers 4.9 · 3rd of 8
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 7.01
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Divis Laboratories a quality business?

Quality score 63.6, 1st of 12 in its peer set; WATCH on 30 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 63.6
vs peers 47.1 · 1st of 12
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 16.5%
vs peers 13.3% · 4th of 12
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 21.4%
vs peers 14.5% · 2nd of 12
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 25.0%
vs peers 13.8% · 1st of 12
Profit after everything, as a share of revenue. Learn more →
EPS ₹96.91
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Divis Laboratories made money for shareholders?

Yes: +42.5% over one year and +14.1% a year over five years.

Shareholder returns

1-year return +42.5%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +14.1% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer No
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
+1.6%
1M
+1.5%
3M
+34.6%
6M
+53.9%
1Y
+42.5%
3Y
+40.0%
5Y
+14.1%

Does Divis Laboratories pay a dividend?

Yes. Divis Laboratories's dividend yield is 0.50% at the latest price; the last payout was ₹30.00 a share, ex-dividend 24 Jul 2026.

Dividends

Per share, by ex-dividend date
Dividend yield0.50%
The past 12 months' dividends as a share of today's price.
24 Jul 2026 · Final₹30.00
25 Jul 2025 · Final₹30.00
2 Aug 2024 · Final₹30.00
11 Aug 2023 · Final₹30.00
11 Aug 2022 · Final₹30.00
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Divis Laboratories growing?

Revenue 3 years 10.9% a year; profit 3 years 12.1% a year; revenue 5 years 5.2% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 10.9% a year
vs peers 11.5% · 7th of 12
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 12.1% a year
vs peers 20.2% · 8th of 12
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 5.2% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years -0.2% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 12.1% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 5.3% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history 48.0%
vs peers 1.5% · 11th of 12
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Divis Laboratories do last quarter?

Divis Laboratories reported revenue of ₹3,080 Cr, up 12.8% on a year earlier and a net profit of ₹902 Cr, up 17.2% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹3,080 Cr
+12.8% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹902 Cr
+17.2% on a year earlier
What was left for shareholders after every cost and tax.

How does Divis Laboratories compare with its peers?

Compared with 11 Pharmaceuticals; 11th of 12 on P/E; 1st of 12 on quality score.

Compared with 11 Pharmaceuticals

11 companies

Divis Laboratories against its peers

Largest 10 of 11 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Divis Laboratories Ltd₹2.5 L Cr84.89.416.5%21.4%+42.5%
Sun Pharmaceutical Industries Ltd₹4.2 L Cr34.918.912.7%14.5%+5.5%
Torrent Pharmaceuticals Ltd₹1.8 L Cr74.316.927.3%19.2%+32.4%
Zydus Lifesciences Ltd₹1.1 L Cr24.93.715.9%15.9%+12.3%
Laurus Labs Ltd₹1.1 L Cr100.510.215.1%14.9%+132.9%
Cipla Ltd₹1.1 L Cr31.22.910.6%13.9%−16.8%
Dr Reddys Laboratories Ltd₹99,911 Cr30.93.310.7%12.6%−5.2%
Mankind Pharma Ltd₹97,830 Cr47.95.013.3%13.1%−3.0%
Aurobindo Pharma Ltd₹97,411 Cr26.43.311.2%12.9%+48.9%
Lupin Ltd₹89,469 Cr15.83.523.4%27.5%−0.8%
Glenmark Pharmaceuticals Ltd₹64,714 Cr36.02.53.9%6.3%+20.1%
Peer median—31.23.713.3%14.5%+5.5%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Divis Laboratories?

Divis Laboratories is held by promoters 51.9%, foreign institutions 20.4%, domestic institutions 19.2%.

Shareholding pattern

Latest filing, percent of shares
Promoters51.9%
The founders and controlling group.
Foreign institutions20.4%
Overseas funds investing through the FPI route.
Domestic institutions19.2%
Indian insurers, banks, pension and mutual funds together.
Mutual funds14.7%
Indian mutual fund schemes; part of domestic institutions.
Retail and others6.1%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Divis Laboratories?

26 analysts cover Divis Laboratories, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

26 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Divis Laboratories do and what is it sensitive to?

Divi's Laboratories makes generic active pharmaceutical ingredients (APIs), custom-synthesis APIs and intermediates, and nutraceutical ingredients, and sells them to pharmaceutical and nutraceutical companies that turn them into finished products. Sensitive to: INR/USD exchange rate.

Business-model card

FY2025 · 45 verified
4Revenue
4Channels
3Regulators
5Reg. dependencies
5Sensitivities
4Costs
5Geographies

Divi's Laboratories makes generic active pharmaceutical ingredients (APIs), custom-synthesis APIs and intermediates, and nutraceutical ingredients, and sells them to pharmaceutical and nutraceutical companies that turn them into finished products. It earns through product sales and contract manufacturing, with exports at 88% of turnover.

Revenue engine

4 verified
Generic APIs
Selective portfolio of generic APIs made at scales from tens to thousands of metric tonnes a year and supplied to customers in more than 100 countries.
Custom Synthesis (contract manufacturing)
Contract manufacture of APIs and intermediates for global pharmaceutical innovators, under customer specifications; Interpretation: earns per contracted project rather than on own-brand product.
Nutraceuticals
Nutraceutical ingredients, listed as one of three core business portfolios alongside generic APIs and custom synthesis.
1 more statement
Contrast Media segment
Company describes a Contrast Media segment built on manufacturing iodine-based compounds and gadolinium-based MRI contrast agents; Interpretation: revenue size not stated in these excerpts.

Customers & channels

4 verified
Pharmaceutical and nutraceutical companies (B2B)
Customers are manufacturers who further process the supplied API or intermediate into finished products, so they are business buyers rather than consumers.
Small number of large customers
Relatively few large B2B customers; Interpretation: concentration means loss or change of one buyer moves revenue materially.
Single external customer above 10% of revenue
One external customer exceeded 10% of revenue from operations in FY 2024-25, as stated on the group basis.
1 more statement
Innovator pharma outsourcing (Big Pharma custom synthesis)
Several major Big Pharma custom synthesis projects are moving into full-scale production, so these customers drive custom-synthesis volumes.

Regulators

3 verified
US FDA, EMA and other stringent regulators
Frameworks that Indian CDMOs must comply with; the company says it accesses advanced markets such as Europe and USA for a major part of its business.
Regulatory compliance in US and Europe
Company states regulatory compliance in advanced markets is inherent to its business; non-compliance would hit the export revenue that is most of sales.
Drug and Cosmetics Act, 1940
Listed among other applicable Acts for the company's operations.

Regulatory dependencies

5 verified
US tariff adjustments and trade policy
Interpretation: a tariff change on exports into the US would move export revenue and margins, since the company reports that the revenue mix is largely exports.
Biosecure Act policy reforms
Interpretation: policy reform affecting supply into US healthcare could shift which CDMOs get contracts, and so customer volumes.
Protective actions by recipient-country governments
Company says export exposure means it will be affected by protective actions of governments in recipient countries, which would cut export sales.
2 more statements
Duty drawback export incentive
Export incentives are duty drawback recognised as income when the right to credit is established; a scheme change would move other operating revenue (FY2025 export incentives of 2 crore).
Environment, health and safety compliance cost
Complex chemical reactions create EHS compliance risk; Interpretation: stricter environmental rules would raise process and waste-handling cost.

Sensitivities

5 verified
INR/USD exchange rate
Per the company's sensitivity table, a 2% INR/USD increase shows a (24) crore impact on profit after tax, and a 2% decrease shows 24 crore; direction: a stronger rupee reduces the profit impact positively and a weaker rupee raises it.
Export exposure and imports of inputs
Large export revenue and imported inputs create large foreign-exchange exposure; Interpretation: rupee moves change both revenue and input cost.
Rupee depreciation history
Company notes the rupee has historically depreciated and therefore takes no additional hedge; a rupee appreciation would be unhedged.
2 more statements
Interest rates
No long-term borrowings, so the company states no exposure to interest rate risk; a rate change has no direct effect on its debt cost.
Forex gains in other income
Net gain on forex transactions and translations was 48 crore in FY2025 against 28 crore the prior year, so currency moves feed reported profit as well as sales.

Cost inputs

4 verified
Raw material and starting-material consumption (40.0%)
Material consumption net of stock change is about 39.98% of revenue from operations, the largest cost line; the company says it varies by product.
Purchased raw materials
Raw materials are bought (purchases) and reduced by opening and closing stock; the standalone note records total raw-material cost of 3,760 crore.
In-house starting materials (backward integration)
Most key starting materials are made in-house, reducing dependence on external suppliers; the company says this optimises cost and pricing competitiveness.
1 more statement
Foreign-currency payables to suppliers
Supplier payables are partly in foreign currencies, so input costs also move with exchange rates.

Geographies

5 verified
Europe (57.0%)
Largest sales region; company accesses Europe for a major part of its business and reports Europe revenue of 5,265 crore in FY2025.
America (USA) (16.0%)
Second-largest sales region in the company's geography split; USA revenue is also reported separately in the group notes.
India (12.0%)
Domestic sales region; Indian revenue from contracts with customers is 1,105 crore in FY2025.
2 more statements
Asia
Sales region, share stated as 11% in the geography split.
Subsidiary Divis Laboratories (USA) Inc
Wholly owned subsidiary in the USA, held 100% by the group per the consolidation note.
Each statement is checked word for word against the FY2025 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (1 Aug 2026).

Change log

8 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Corporate actionDividend - Rs 30 Per Share.
  3. Results filedQ4 FY2026 results filed.
  4. Results filedQ3 FY2026 results filed.
  5. Results filedQ2 FY2026 results filed.
  6. Results filedQ1 FY2026 results filed.
  7. Corporate actionDividend - Rs 30 Per Share.
  8. Results filedQ4 FY2025 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsWATCH on 30 of 30 flags judged; 1 red.
  • Data gapsBusiness quality: not available yet.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓283 months of month-end prices, adjusted for bonuses and splits (3 corporate actions)○no valuation of ours yet✓business-model card FY2025 · 45 verified

Questions people ask

What is Divis Laboratories's share price today?

Divis Laboratories last traded at ₹9,426.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, up 0.9% on the day, up 42.5% over a year. Its 52-week range is ₹5,648 to ₹9,740. The live price is in the app.

What is Divis Laboratories's market cap?

Divis Laboratories's market capitalisation is about ₹2.48 lakh crore: what it would cost to buy every share at today's price. That makes it the 35th largest large cap company we cover.

Is Divis Laboratories Ltd a large cap, mid cap or small cap?

Divis Laboratories Ltd (DIVISLAB) is a large cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Divis Laboratories Ltd's P/E ratio?

84.75, vs peers 31.2 · 11th of 12. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Divis Laboratories Ltd overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 84.8 vs peers 31.2 (11th of 12); P/B 9.4 vs peers 3.7 (9th of 12).

How does Divis Laboratories Ltd make money?

Divi's Laboratories makes generic active pharmaceutical ingredients (APIs), custom-synthesis APIs and intermediates, and nutraceutical ingredients, and sells them to pharmaceutical and nutraceutical companies that turn them into finished products. It earns through product sales and contract manufacturing, with exports at 88% of turnover.

Who are Divis Laboratories Ltd's peers?

Compared with 11 Pharmaceuticals: Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Zydus Lifesciences Ltd, Laurus Labs Ltd, Cipla Ltd and 6 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Divis Laboratories do last quarter?

Divis Laboratories reported revenue of ₹3,080 Cr, up 12.8% on a year earlier and a net profit of ₹902 Cr, up 17.2% in the Jun 2026 quarter.

Who owns Divis Laboratories?

Divis Laboratories is held by promoters 51.9%, foreign institutions 20.4%, domestic institutions 19.2%.

Does Divis Laboratories pay a dividend?

Yes. Divis Laboratories's dividend yield is 0.50% at the latest price; the last payout was ₹30.00 a share, ex-dividend 24 Jul 2026.

What do analysts say about Divis Laboratories?

26 analysts cover Divis Laboratories, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Everything on Divis Laboratories, and 6,621 other companies, with 212 filters and the full peer tables

See Divis Laboratories in the app →See pricing